Search

Search Constraints

You searched for: Author/Creator Licata, Stephanie

Search Results

4. 086 The rapid efficacy of natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): results from reveal, a randomised, head-to-head study. Issue 6 (24th May 2018)

6. A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis. (December 2021)

8. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). Issue 6 (31st March 2020)

9. Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. Issue 10 (20th October 2020)

10. Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. Issue 10 (20th October 2020)